COMPLETED

Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is a single center, prospective, randomized, open-label study aimed at determining the most effective means of preventing hypersensitivity reactions in gynecologic oncology patients receiving paclitaxel infusions. The study will therefore provide clinicians with the best ways of preventing paclitaxel hypersensitivity reactions in their patients during treatment. Subjects will be randomized using the block randomization method into one of these three commonly used treatment methods:(1) Conventional method: oral dexamethasone (20 mg), taking 12 hours and 6 hours prior to paclitaxel infusion and intravenous administration of histamine-1 (H1), and a histamine-2 (H2)receptor antagonists administered 30 minutes prior to paclitaxel infusion. (2) Short-course method: intravenous dexamethasone (20 mg), administered concurrently with H1 and H2 antagonists, 30 minutes prior to paclitaxel infusion. (3) Combined method: oral dexamethasone (20 mg), taking 12 hours prior to treatment in addition to intravenous dexamethasone (20 mg), H1 and H2 receptor antagonists administered 30 minutes prior to paclitaxel infusion. The one-way analysis of variance (ANOVA) would be used to determine if there is any significant difference between the different strategies that are used to pre-medicate patients prior to paclitaxel infusion. P-values of less than 0.05 will be considered statistically significant.

Official Title

Conventional Prophylactic Regimen of Oral Dexamethasone Versus Short-course Intravenous Dexamethasone in Preventing Paclitaxel-related Hypersensitivity Reactions in Breast and Gynecologic Oncology Patients

Quick Facts

Study Start:2018-08-08

Study Completion:2025-01-07

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT03598426

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:FEMALE

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Adult female patients \> 18 years of age 2. Patients of the Loma Linda University Health (LLUH) gynecologic oncology and breast oncology service 3. Confirmed breast or gynecologic cancer diagnosis of any stage and any gynecologic or breast malignancy 4. Planned treatment with paclitaxel containing regimen either in the adjuvant setting or for palliation 5. Planned treatment with paclitaxel should be for 3 or more cycles given as a weekly or every 3 weeks cycle 6. Paclitaxel should be given as a monotherapy or as part of a combination regimen. If paclitaxel is part of a regimen containing other drugs, the following conditions must be met: 1. Paclitaxel will be the first chemotherapy regimen to be infused when patient comes in for treatment 2. Chemotherapy regimen that would be approved for the study are the following: 7. Patients should have no prior exposure to taxanes (this includes: paclitaxel, docetaxel, and protein-bound paclitaxel) 8. The chemotherapy treatment should be at one of the LLUH Adult Cancer Centers 9. The patient should be an English or Spanish speaking patient	1. Patients who are not with the gynecologic or breast oncology service 2. Patients who are with the gynecologic oncology or breast oncology service but are not receiving paclitaxel either as a monotherapy or in combination with other regimen 3. Patients who have had prior exposure to taxanes (this includes: paclitaxel, docetaxel, and protein-bound paclitaxel) 4. Patients who are currently on steroid therapy and it is anticipated that therapy will not be discontinued at least a week prior to start of chemotherapy 5. Patients with autoimmune diseases, malignancies, and any other co-morbid condition that might require steroid therapy during chemotherapy. This includes, but not limited to: 1. Crohn's disease 2. Immune thrombocytopenia 3. Lupus nephritis 4. Multiple sclerosis 5. Primary brain tumors 6. Multiple Myeloma 7. Hodgkin's Lymphoma 6. Patients with uncontrolled diabetes or diabetic or pre-diabetic patients with baseline A1C levels \> 8.5 7. Patients who are allergic to diphenhydramine and/or dexamethasone 8. Non-English and Non-Spanish speaking patients

Inclusion Criteria

Exclusion Criteria

1. Adult female patients \> 18 years of age
2. Patients of the Loma Linda University Health (LLUH) gynecologic oncology and breast oncology service
3. Confirmed breast or gynecologic cancer diagnosis of any stage and any gynecologic or breast malignancy
4. Planned treatment with paclitaxel containing regimen either in the adjuvant setting or for palliation
5. Planned treatment with paclitaxel should be for 3 or more cycles given as a weekly or every 3 weeks cycle
6. Paclitaxel should be given as a monotherapy or as part of a combination regimen. If paclitaxel is part of a regimen containing other drugs, the following conditions must be met:
1. Paclitaxel will be the first chemotherapy regimen to be infused when patient comes in for treatment
2. Chemotherapy regimen that would be approved for the study are the following:
7. Patients should have no prior exposure to taxanes (this includes: paclitaxel, docetaxel, and protein-bound paclitaxel)
8. The chemotherapy treatment should be at one of the LLUH Adult Cancer Centers
9. The patient should be an English or Spanish speaking patient

1. Patients who are not with the gynecologic or breast oncology service
2. Patients who are with the gynecologic oncology or breast oncology service but are not receiving paclitaxel either as a monotherapy or in combination with other regimen
3. Patients who have had prior exposure to taxanes (this includes: paclitaxel, docetaxel, and protein-bound paclitaxel)
4. Patients who are currently on steroid therapy and it is anticipated that therapy will not be discontinued at least a week prior to start of chemotherapy
5. Patients with autoimmune diseases, malignancies, and any other co-morbid condition that might require steroid therapy during chemotherapy. This includes, but not limited to:
1. Crohn's disease
2. Immune thrombocytopenia
3. Lupus nephritis
4. Multiple sclerosis
5. Primary brain tumors
6. Multiple Myeloma
7. Hodgkin's Lymphoma
6. Patients with uncontrolled diabetes or diabetic or pre-diabetic patients with baseline A1C levels \> 8.5
7. Patients who are allergic to diphenhydramine and/or dexamethasone
8. Non-English and Non-Spanish speaking patients

Contacts and Locations

Principal Investigator

Linda Hong, MD

PRINCIPAL_INVESTIGATOR

Loma Linda University Cancer Center

Study Locations (Sites)

Loma Linda University Cancer Center

Loma Linda, California, 92354

United States

Collaborators and Investigators

Sponsor: Loma Linda University

Linda Hong, MD, PRINCIPAL_INVESTIGATOR, Loma Linda University Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-08-08

Study Completion Date2025-01-07

Study Record Updates

Study Start Date2018-08-08

Study Completion Date2025-01-07

Terms related to this study

Additional Relevant MeSH Terms

Hypersensitivity Reactions